Medications

FDA approves first biosimilar drug in US

(HealthDay)—The U.S. Food and Drug Administration has approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.

Oncology & Cancer

Researchers to test 'breakthrough' pediatric leukemia treatment

A promising method of immunotherapy to treat children with relapsed acute lymphocytic leukemia (ALL) is opening at the University of Wisconsin Carbone Cancer Center and American Family Children's Hospital. The trial is open ...

Oncology & Cancer

Could there be a gleevec for brain cancer?

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically ...

Oncology & Cancer

Blincyto approved for rare leukemia

(HealthDay)—Blincyto (blinatumomab) has been approved by the U.S. Food and Drug Administration to treat Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, a rare cancer of the bone marrow.

Oncology & Cancer

'Dramatic' early phase 1 results for AG-120 in IDH1 mutated AML

Results presented November 19 by University of Colorado Cancer Center investigator Daniel Pollyea, MD, MS, at the 26th European Organisation for Research and Treatment of Cancer Symposium in Barcelona show "extremely promising" ...

Oncology & Cancer

A new approach to fighting chronic myeloid leukemia

Chronic myeloid leukemia develops when a gene mutates and causes an enzyme to become hyperactive, causing blood-forming stem cells in the bone marrow to grow rapidly into abnormal cells. The enzyme, Abl-kinase, is a member ...

Oncology & Cancer

AACR: tumor vulnerability varies with clonal evolution in ALL

(HealthDay)—In acute lymphoblastic leukemia (ALL), tumor vulnerability to different chemotherapeutic agents varies at different stages of clonal evolution, which could represent a viable strategy in avoiding drug resistance. ...

Oncology & Cancer

Novel cancer drug proves safe for leukemia patients

Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy. The findings, reported by doctors at Wake Forest Baptist Medical Center, ...

page 16 from 26